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Introduction
Transcatheter aortic valve implantation (TAVI) has become the 'standard of care' for the treatment of high risk and surgically inoperable patients with symptomatic aortic stenosis (AS). The PARTNER 2 [1] trial has also recently demonstrated that TAVI is non-inferior to surgical aortic valve replacement (sAVR) in the 'intermediate risk' group. The number of TAVIs performed world-wide is therefore likely to increase significantly in the near future. Moreover, recent years have seen impressive reductions in complications of TAVI and consequent improvements in outcomes and survival, which was evident in PARTNER 2. TAVI is becoming a more straightforward and reproducible procedure and the move towards conscious sedation, smaller delivery systems and improvements in percutaneous closure techniques have allowed TAVI patients to mobilize soon after the procedure, facilitating early discharge. Early discharge of TAVI patients will improve cost-effectiveness; data already indicate that despite greater procedural costs, TAVI is cost-effective compared with sAVR over a 10-year period, due to the greater post-procedural cost of sAVR [2] . In order to respond to an increasing Omar Aldalati et al., Early discharge after TAVI demand for TAVI and to improve the efficiency of our patient pathway, this research sought to study the factors associated with safe early discharge in a "real world" population after the TAVI procedure.
Methods
All cases analyzed were done between August 2007 and March 2015. Each patient was selected for TAVI by a multidisciplinary Heart Team that consisted of specialist nurses, interventional and imaging Cardiologists and Cardiothoracic Surgeons. Patients underwent pre-TAVI work up including trans-oesophageal echocardiography, coronary angiography and peripheral angiography as well as computed tomography (CT) aortography. The aortic valve annulus was sized using three-dimensional (3D) trans-oesophageal echocardiography. This was the first centre in the United Kingdom to implant an Edwards Sapien valve (Edwards Lifesciences, Irvine, California) and, as such, it is the predominantly used prosthesis herein. During the study period, general anaesthetics had been the default method of anaesthesia and only 2 cases were performed under conscious sedation.
From 2007 to 2012, patients were routinely monitored on the Intensive Care Unit post-TAVI. Since October 2012, patients have been cared for on a level-two unit post-TAVI such as Coronary Care Unit/High Dependency Unit. Presented protocol mandates a minimum 24 h stay in a level two ward followed by a step-down to a cardiology/ /cardiothoracic ward (level one) with early mobilisation and physiotherapy. On day one or two (day of index procedure is day 0), patients undergo transthoracic echocardiography. If clinically stable, the majority of patients will be considered for planned discharge on day two.
Patient demographics, detailed procedural characteristics, hospital stay and outcomes are recorded prospectively on a national database and reported according to Valve Academic Research Consortium-2 (VARC-2) criteria [3] . Mortality and re-admission rates were obtained from local and national databases. Based on length of hospital stay, cases were classified into early discharge (≤ 3 days) and late discharge (> 3 days). In order to devise an early discharge protocol, a "safe outcome" measure was created: -"Safe outcome at 30 days" was defined as absence of: 1) pacing post discharge up to 30 days, 2) any cause re-admission up to 30 days, and 3) any cause mortality up to 30 days.
-"Safe outcome at 1 year" was defined as absence of: 1) pacing post discharge up to 1 year, 2) any cause re-admission up to 1 year, and 3) any cause mortality up to 1 year.
Statistical analysis
Continuous variables are expressed as means and standard deviations. Parametric and nonparametric tests were used based on sample size and normality of distribution. Categorical data are expressed as percentages. Univariable analysis using c 2 , Fisher exact, or t test, ANOVA and other non-parametric tests were used to identify differences between early and late discharge groups.
Multiple imputations were used to replace missing data when the variable had less than 10% missing values. "Automatic Imputation Method" was used with five imputations. Pooled data were analyzed.
In order to determine the factors associated with early discharge, logistic regression model was generated. Seven variables were included in the model to permit for the rule of thumb of "5-9 events per variable" [4] . The variables were chosen based on univariate analysis and what has already been published. The same model was then used to identify predictors of "safe outcome at 1 year".
All analysis was done using SPSS statistical software (IBM Corp. 
Results
From August 2007 until March 2015, 337 TAVI procedures were performed in the above cited center. Eighteen (5.4%) patients died in hospital. Fifty-six (56/319; 17.5%) patients were discharged home early (≤ 3 days post-procedure). Figure 1 shows the number of days spent in hospital. The baseline characteristics of the study group are summarized in Table 1 . Just over half of our patients were male (50.2%). The mean age was 82.58 ± 6.7 years. The mean hospital stay was 9.4 ± 9.7 days (mode 3 days, median 6 days). The median hospital stay among the early discharge group was 3 (interquartile range [IQR]: 3-3) days and among late discharge group 7 (IQR: 5-13) days, p < 0.0001.
During the study period, the mean sheath size dropped significantly from 24 mm to 17 mm (p < 0.0001) and the percentage of trans-apical cases performed decreased from 51% to 17.4% (p < 0.0001). Moreover, the mean logistic Euro-SCORE also dropped (22 to 15, p < 0.0001). The above changes were associated with a significant rise in the percentage of early discharge (2% to 32%, p < 0.0001) and a reduction in the overall mean hospital stay (11.4 to 7.1 days, p < 0.0001). Only two cases were done under conscious sedation, both were performed in March 2015 and were discharged early.
Patients discharged early had a lower New York Heart Association (NYHA) class III/IV (48% vs. 66%, p = 0.001), lower rates of peripheral vascular disease, lower baseline creatinine and a lower mean logistic EuroSCORE (16.7 vs. 21.7, p = 0.001) ( Table 1) . Echocardiographic features showed less aortic valve (AV) calcification and a larger AV area in the early discharge group (Table 1) .
The procedural characteristics were also different between the two groups. Among patients discharged early, the trans-apical route was used less, the sheath size was smaller, the duration of rapid pacing was shorter periprocedurally, and percutaneous closure devices were more frequently used ( Table 2 ). Patients discharged early had a shorter level-two stay (0.93 vs. 1.43 days, p < 0.0001).
Adjudicated according to VARC-2 criteria, life-threatening bleeding and acute kidney injury (AKI) stage II or III were higher among late discharge group at 30 days. There were no deaths among the early discharge group within 30 days of discharge and 3 (1.1%) patients died from the late discharge group (p = 1). Within 1 year, 2 (3.6%) and 41 (15.6%) patients died, respectively (p = 0.014); Table 3 summaries outcomes according to VARC-2 criteria.
Moreover, patients in the early discharge group required less blood transfusion, and had lower delta creatinine (the difference between the highest creatinine level after the procedure and the level before) and a lower hemoglobin drop post-TAVI, a potential surrogate marker for bleeding (Table 3) .
Using multivariable logistic regression, the following factors were associated with early discharge: logistic EuroSCORE (odds ratio [OR] 0.947, 95% confidence interval [CI] 0.912-0.983, p = 0.004), delta creatinine (OR 0.967, 95% CI 0.949-0.985, p < 0.0001) and development of any complication as defined by an occurrence of any of the following -stroke, major or life threatening bleeding, major vascular injury, AKI stage II/III or the need for pacing (OR 0.174, 95% CI 0.048-0.630, p = 0.008). Factors such as prior pacing, NYHA class and bleeding did not influence early discharge in this heterogenous group of patients when accounting for other variables. Table 4 summarizes univariate and multivariate predictors of early discharge.
All-cause re-admission rate and the need for permanent pacing after discharge were also studied. In the early discharge group, only 2 patients required re-admission within 30 days (2/56, 3.6%) whilst there were 25 re-admissions among the late discharge group (25/263, 9.5%, p = 0.19). The early discharge group had 9 (16.1%) admissions between 30 days and 12 months after discharge whilst the late discharge group of patients had 56 (21.3%) admissions during the same period (p = 0.4). 64% and 54% of these re-admissions were car- Omar Aldalati et al., Early discharge after TAVI diovascular in origin at 30 days and 12 months, respectively (causes of these admissions are shown in Table 5 ). Up to 30-days post discharge, 2 (3.6%) patients out of 56 needed permanent pacing in the early discharge group but only 1 (0.4%) patient in the late discharge group. By 12 months, 2 (3.6%) more patients required permanent pacing in the early discharge group and 4 (1.5%) in the late discharge group (p = 0.56).
"Safe outcome at 30 days and 1 year" was reached in 287 (90%) and 213 (67%) cases respectively in the overall cohort. At 30 days, 93% of early discharge patients had safe outcomes vs. 89% in the late discharge group (p = 0.62), and 
Discussion
Despite high risk characteristics of this patient group, the present data and the recently published works by Durand et el. [5] and Barbanti et al. [6] suggest that early discharge (≤ 3 days) is a feasible and safe option after TAVI. Factors associated with early discharge seem to be consistent in these studies and they overlap with predictors of "safe outcome". Combining these factors/predictors, it was possible to create a protocol to facilitate early discharge (Fig. 2) .
One of the major concerns post-TAVI is the risk of potentially dangerous conduction abnormalities. According to Khawaja et al. [7] , the overall median time to permanent pacemaker implantation post TAVI was 4 days. However, this study looked at CoreValve prostheses (Medtronic, Minneapolis, Minnesota, USA) the use of which is associated with higher rates of pacing than following Edwards Sapien implantation. Another study utilizing both self-expanding and balloon-expandable TAVI valves has shown that pacemaker requirement becomes apparent at 4 days [8] . However, neither studies report on the time of diagnosis of conduction defects post TAVI. This study indicates that early discharge does not increase the risk of re-admission for pacemaker implantation. Presumably, this suggests that conduction defects become evident early post TAVI i.e. in the first 3 days.
The negative impact of bleeding and blood product transfusion on hospital stay with a variety of cardiac procedures is well known and its influence on the TAVI patient cohort is also recognized. Barbanti et al. [6] demonstrated that lack of significant bleeding is a predictor of early discharge whilst Durand et al. [5] demonstrated that requirement of blood transfusion post-TAVI was a negative predictor of early discharge. The present group of patients was more heterogenous than those included in these studies and, as such, neither bleeding nor transfusion feature as significant predictors of early discharge on multivariate analysis. Nonetheless, improving procedural techniques to reduce bleeding and blood transfusion are likely to improve rate of early discharge. GI bleed 2 (0.6%) 0 2 (0.6%) 1 *Based on stroke events. $ There were three cases of upper gastrointestinal bleeds that were not related to transcatheter aortic valve replacement (TAVI); GI -gastro-intestinal, creatinine (umol/L), hemoglobin (g/L); AKI -acute kidney injury; N/A -not applicable; NYHA -New York Heart Association; VARC-2 -Valve Academic Research Consortium-2; TIA -transient ischemic attack
The predictive value associated with serum creatinine seems consistent in this study and others [5, 6] . AKI post-TAVI is associated with increased mortality [9] but studies on outcome post-TAVI and chronic kidney disease have shown inconsistent results [10, 11] thus far. The influence of these conditions on hospital stay has not been studied in detail. The reported OR on post-TAVI delta creatinine demonstrates clearly that AKI has a negative impact on early discharge rates.
The occurrence of any complication influence discharge. It is noteworthy that Durand et al. [5] showed that most of the major complications post TAVI occurred within 48 h after the procedure i.e. patients who developed complications were known by day three and therefore not discharged. The study also reports that only 3 patients had delayed major complications.
Based on current evidence, factors associated with early discharge are therefore prior pacemaker (OR 2.27-2. This study demonstrates that clinically selected early discharge is associated with similar allcause re-admission rate, similar 30-day mortality and similar re-admission rate for permanent pacing. These findings are consistent with other published studies [5, 6] . It also shows that early discharge is associated with a safe outcome for up to 1 year. The current trend in practice towards conscious sedation may influence the early discharge rate further; nonetheless, the present experience shows safe early discharge even for those performed under general anaesthesia. Overlap between factors associated with early discharge and predictors of safe outcome provides us with an opportunity to devise a clinical protocol that incorporates these predictors (Fig. 2) . Safe early discharge is likely to significantly improve cost-effectiveness of TAVI. Babaliaros et al. [12] , as demonstrated previously, that with a 'minimalist approach' with TF TAVI, shorter length of stay translated into lower resource use and significantly lower hospital costs. The same is likely to apply to early discharge. This is a retrospective observational study with the inherent limitations of any observational study. Physical performance status and family support are significant confounders of early discharge among the elderly TAVI patients. Assessment of frailty and quality of life was introduced recently into the TAVI practice and as such quantifying these important social issues in retrospect is difficult and was not included in the analysis.
All patients included who received this technology throughout its evolution and practice has changed significantly. It is well known that the TAVI procedure in the current era is significantly different from 2007 and as such it is appreciated Omar Aldalati et al., Early discharge after TAVI 
